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The human genome is epigenetically organized through a series of modiﬁcations to the histone proteins that interact with the
DNA. In cancer, many of the proteins that regulate these modiﬁcations can be altered in both function and expression. One
example of this is the family of histone deacetylases (HDACs), which as their name implies remove acetyl groups from the histone
proteins, allowing for more condensed nucleosomal structure. HDACs have increased expression in cancer and are also believed
to promote carcinogenesis through the acetylation and interaction with key transcriptional regulators. Given this, small molecule
histone deacetylases inhibitors have been identiﬁed and developed, which not only inhibit HDACs, but can also lead to growth
arrest, diﬀerentiation, and/or apoptosis in tumors both in vitro and in vivo. Here, we will discuss some of the recent developments
in clinical trials utilizing HDACs inhibitors for the treatment of both hematological malignancies as well as solid tumors.
1.Introduction
DNA is woven together with proteins into an intricate
organization of both extended euchromatin and condensed
heterochromatin. The posttranslational modiﬁcations of the
histone proteins involved in this structure regulate the
epigenetic organization of the genome. This genomic orga-
nization is often altered on an epigenetic level, including the
phosphorylation, acetylation, methylation, ubiquitination,
sumoylation, and ADP-ribosylation of the eight histones
within the nucleosome (H2A, H2B, H3, and H4).
In 1964, Mirsky and Allfrey published the ﬁrst reports
of histone acetylation and methylation being involved in
RNA synthesis in a reversible fashion and being highly
associated with open chromatin [1, 2]. Today, it is known
that histone acetyltransferases transfer the acetyl group from
acetyl-CoA forming ε-N-acetyl lysine on conservedlysines of
the N-terminal tails of histones H3 and H4 (and to a lesser
extent H2A and H2B), resulting in an open nucleosomal
structure. This can be reversed by histone deacetylases
( H D A C s )o fw h i c h ,i nm a m m a l s ,t h e r ea r ec u r r e n t l y1 8
identiﬁed and have been divided into four classes based
on cellular localization and function [3]. Class I includes
HDACs 1, 2, 3, and 8 which are all nuclear and ubiquitously
expressed. Class II, being able to shuttle back and forth
between the nucleus and the cytoplasm and believed to
be tissue restricted, includes HDACs 4, 5, 6, 7, 9, and 10;
within this class, HDACs 6 and 10 (class IIb) have two
catalytic sites, are expressed only in the cytoplasm, and
are involved in a variety of biological processes. Class III
contains the structurally diverse NAD+-dependent sirtuin
family, which does not act primarily on histones [4]. Finally,
the ubiquitously expressed HDAC11 represents Class IV,
which haspreviouslybeencharacterizedasbeingpartofboth
Class I and Class II (Figure 1). Nonhistone targets of HDACs
includep53, E2F,GATA-1, YY1, RelA,Mad-Max, c-Myc, NF-
κB, HIF-1α, Ku70, α- t u b u l i n ,S T A T 3 ,H s p 9 0 ,T F I I E ,T F I I F ,
and hormone receptors explaining the diverse biological2 Journal of Biomedicine and Biotechnology
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Figure 1: The histone deacetylase, family. Schematic representations of class I (HDAC1, 2, 3, and 8), class II (HDAC4, 5, 6, 7, 9, and 10),
class III (SIRT1), and class IV (HDAC11). Structure and Length of HDACs are shown. The total number of amino acid residues (aa) is
depicted on the right, next to each HDAC. The enzymatic domains and the nucleus localization sequences are highlighted in brown and
black, respectively.
eﬀects that HDACs can impart to the cell ([5–17]f o rr e v i e w ,
see [18, 19]).
K n o c k o u tm i c ef o rH D A C s1a n d2d i s p l a ye m b r y o n i c
or perinatal lethality and class II HDACs knockouts, while
viable and fertile (except for HDAC7) have signiﬁcant
developmental abnormalities [20–22]. HDACs expression,
and activity can be altered in many cancers and in both lym-
phoma and leukemia HDACs is associated with the function
of oncogenic-translocation products, such as PML-RARα in
acute promyelocytic leukemia [23–25]. Furthermore, with
the discovery of speciﬁc pan-HDACs inhibitors, it has been
shown that blocking HDACs function can cause cell-cycle
arrest and diﬀerentiation through the increased expression
of p21WAF1/CIP1 [26, 27], aﬀect tumor survival by blocking
angiogenesis through the increased acetylation of HIF-1α
[9], aﬀect protein degradation through the acetylation of
Hsp90 [13], and increase the expression of pro-apoptotic
factors [28–31], making HDACs inhibitors a good candi-
date for single-agent cancer therapy and even combination
therapy with conventional chemotherapeutics and radiation.
Here, we will discuss the latest clinical advances in HDACs
inhibitors.
2.HDACsInhibitor Classiﬁcations
Riggs and colleagues identiﬁed the HDACs inhibitor pro-
totype sodium butyrate to be an eﬀective inhibitor of
deacetylase activity [32, 33]. This was found to be non-
competitive, reversible and speciﬁc for HDACs activity [34–
36]. Sodium butyrate was also found to induce diﬀeren-
tiation, RNA synthesis and strongly inhibit cell growth in
the G1 phase of the cell cycle [37]. These ﬁndings paved
the road for development of more speciﬁc and eﬀective
HDACs inhibitors to use in the clinic. HDACs inhibitors
can be divided into four major structural classes: (1) small
molecular weight carboxylates; (2) hydroxamic acids; (3)
benzamides; and (4)cyclicpeptides [19,38,39].Pan-HDACs
inhibitors include vorinostat, panobinostat, belinostat and
isotype/class-speciﬁc HDACs inhibitors include romidepsin,
mecetinostat (MGCD0103) and entinostat [39]. Vorinostat
(Zolinza) and Romidepsin (Istodax) are the only HDACs
inhibitors currently approved by the U.S. Food and Drug
Adminitration (FDA) for the treatment of refractory cuta-
neous T-cell lymphoma (CTCL) [40, 41].
All HDACs inhibitors available or in development target
the zinc molecule found in the active site of Class I, II,
and IV HDACs and are characterized by their ability to
inhibit the proliferation of transformed cells in culture
and tumor growth in animal models by inducing cell-
cycle arrest, diﬀerentiation, and/or apoptosis (Figure 2).
It has been shown that HDACs inhibitors can selectively
induce the expression of less than 10% of genes, some of
which are involved in the inhibition of tumor growth (e.g.,
p21WAF1,p 2 7 Kip and p16ink4a)[ 19, 26, 38]. Furthermore,
evidence shows that more genes may be repressed after
HDACs inhibitors treatment than activated, this could be
due to a chromatin conformation in a hyperacetylated state
that represses transcription, the release of transcriptional
repressors from HDACs protein complexes, the activation
or inactivation of nonhistone transcriptional repressors
and many other plausible explanations. Unfortunately, the
mechanism of action is not completely elucidated, and there
are also no substantiated HDAC or HAT measurements that
can predict tumor response to HDACs inhibitors treatment.Journal of Biomedicine and Biotechnology 3
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Figure 2: Mechanism of action of histone deacetylases inhibitors. It has been proposed that there are speciﬁc sites in the promoter region
of a subset of genes that recruit the transcription factor complex (TFC) with histone deacetylases (HDACs). With inhibition of HDACs by
HDACsinhibitors,histonesareacetylated, andtheDNAthatistightlywrapped aroundadeacetylated histonecorerelaxes.Theaccumulation
of acetylated histones in nucleosomes leads to increased transcription of this subset of genes, which, in turn leads to downstream eﬀects that
result in cell-growth arrest, diﬀerentiation, and/or apoptosis.
Otherwise, HDACsinhibitorsinducebroad hyperacetylation
in both tumor and normal tissues, which can be used as
a biomarker for drug activity. However, steps will need to
be taken to further characterize the molecular mechanisms
behind HDACs inhibitors function as well as predictive
markers of response to further implement them functionally
in the clinic.
3.HDACsInhibitors inClinicalTrials
Fromthe initial discovery of sodiumbutyrate, therehas been
tremendous interest and investigation in HDACs inhibitors,
today there are at least 15 HDACs inhibitors that are
currently under clinical investigation for both hematological
malignancies and solid tumors, both for single-agent and
combination therapy [42]. Initial molecules included val-
proic acid, phenyl-butyrate, SAHA (vorinostat), trapoxin A,
oxamﬂatin, depudepsin, depsipeptide (romidepsin, Istodax)
and trichostatin A [38, 43], which have paved the way to the
second-generationHDACsinhibitorssuchasthehydroxamic
acids: belinostat (PDX101), LAQ824, and panobinostat
(LBH589), and the benzamides: entinostat (MS-27-275),
CI994, and MGCD0103 (mocetinostat) [44]. Here, we will
discuss some of the recent clinical trials regarding several of
the most promising HDACs inhibitors (Table 1).
4.Vorinostat
In 2006, two phase II trials led vorinostat (Zolinza) to be
approved by the U.S. FDA for the treatment of refractory
cutaneousT-cell lymphoma CTCL [40]. A multicenterphase
IIB trial enrolled a total of 74 patients for progressive,
persistent, or recurrent CTCL who had received at least
two prior therapies. Patients were treated daily with 400mg
of orally administered vorinostat and showed an overall
response rate of 29.7%, a 6.1 month median duration of
response, and a 9.8 month median time to progression
[45]. Similar ﬁndings were published in a phase II study
with a similar patient population [46]. When considering
all patients from these trials together, 26% of patients
experienced thrombocytopenia, 14% anemia, and only 5%
ofpatientsexperienced grade 3 to 5adverse events,including
thrombocytopenia, pulmonary embolism, fatigue, and nau-
sea. The most commonadverse eventswere diarrhea, fatigue,
and nausea. From the larger multicenter trial, 6 patients
continued treatment with vorinostat for 2 years or longer
with continued clinical eﬀect (one complete remission (CR),
four partial remission (PR), and one stable disease (SD))
[47].
A phase II clinical trial tested the use of vorinostat in
other hematological malignancies, includingrelapsed diﬀuse
large B-cell lymphoma (DLBCL), where out of 18 patients,
one resulted in a CR and one in SD with grade 1 and 2
toxicities, but was concluded to have an overall minimal
eﬀectintreatingDLBCL[48].Asecondtrialtestedvorinostat
in patients with lymphoma showing promising results.
Out of 17 patients with relapsed indolent non-Hodgkin’s
lymphoma four patients achieved CR, two had PRs and four
patients remained with SD [49].
A dose-escalation phase I trial was also performed for
oral vorinostat as a single-agent therapy in acute myeloid
leukemia (AML). Out of 41 total patients enrolled, 31
with AML, three with myelodysplastic syndrome (MDS),
four with chronic lymphocytic leukemia (CLL), two with
acutelymphoblastic leukemia,and one with chronic myeloid4 Journal of Biomedicine and Biotechnology
Table 1: Table of HDACs inhibitors discussed in this paper, organized by class (refer to text for references).
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leukemia (CML). The maximum tolerated dose (MTD) was
200mg when given twice daily and 250mg when given three
t i m e sd a i l y ,e a c hg i v e nf o r1 4d a y si na2 1 - d a yc y c l e .T h e
dose limiting toxicities (DLT) were again nausea, vomiting,
and diarrhea. Seven of the patients with AML showed
hematologic responses, including two CRs and two CRs with
incomplete recovery [50].
Vorinostat has also been tested for use in treating several
solid tumors, including platinum-resistant epithelial ovarian
cancer, primary peritoneal carcinoma, and nonsmall cell
lung carcinoma (NSCLC). After encouraging results from
a phase I dose-escalation trial of vorinostat combined with
carboplatin and paclitaxel in advanced solid malignancies,
resulting in 11 out of 25 patients (10 of 19 with NSCLC
and 1 of 4 with head and neck cancer) achieving a PR [51],
a phase II National Cancer Institute-sponsored study has
been carried out and results recently published [52]. This
phase II randomized, double-blinded, placebo-controlled
trial enrolled 94 patients with previously untreated stage
IIIB or IV NSCLC to receive Carboplatin and Paclitaxel with
either Vorinostat (400mg daily on days 1 through 14 of
each treatment cycle) or placebo. In the Vorinostat arm,
a favorable trend toward improvement in median PFS (6
months versus 4,1 months in the placebo arm) and OS
(13 months in the Vorinostat arm versus 9,7 months in
the placebo arm) was clearly shown although at the price
of an increased toxicity. Grade 4 thrombocytopenia was
more frequent in the Vorinostat arm (18% versus 3% in
the placebo arm) as well as grade 2-3 nausea, diarrhea, and
fatigue. Moreover, 26% of patients in the Vorinostat arm
discontinued therapy after the ﬁrst cycle in comparison to
16% of the ones enrolled in the placebo arm. Comparably,
the proportions of patients who completed all 6 cycles
scheduled were 41% and 29%, respectively, for the placebo
and Vorinostat arm.
Several trials also tested the eﬃcacy of Vorinostat as
single agent in diﬀerent solid tumor sites (head and neck,
breast, colorectal, and prostate cancer) and all reported a
considerably high rate of adverse eﬀects limiting the possi-
bility of a reliable eﬃcacy assessment. The most common
adverseeventreportedinthosetrialswere:fatigue(from62%
to 81%), nausea (from 58% to 74%), anorexia (from 58% to
81%), vomiting (from 33% to 56%), and thrombocytopenia
(from 17% to 50%) [53–55].
Vorinostat is potentially also an attractive candidate for
association with radiation since HDACs inhibition decreases
cellular ability to repair DNA double-strand breaks both
by Homologous Repair (HR) and Non-Homologous End
Joining (NHEJ) [56, 57], thus resulting in a potent in vivo
radiosensitizing eﬀect [58]. A Phase I trial recently tested
Vorinostat in combination with pelvic palliative radiother-
apy (3Gy per fraction up to 30Gy) for gastrointestinal
tumors. Vorinostat was administered orally once daily 3
hours before each radiotherapy fraction at doses ranging
from 100mg to 400mg. The most common, any grade,
adverse eﬀects reported were fatigue, nausea, anorexia, and
vomiting, respectively, in 94%, 65%, 59%, and 47% of
patients [59].
5.Romidepsin
Romidepsin (Istodax, Gloucester Pharmaceuticals) is a nat-
ural compound isolated from Chromobacterium violaceum.
It is a bicyclic tetrapeptide and is sometimes referred to as
depsipeptide after the class of molecules to which it belongs.
It was ﬁrst tested for antibacterial activity, but it was found
to have strong cytotoxic activity against diﬀerent tumor cell
lines, and later on mice. Romidepsin is mainly targeting class
I HDACs, and it has also been recently approved by the
FDAfortreatment ofCTCL.Two phase II multicentricsingle
arm trials collected cumulatively167 patients with refractory
CTCL (mostly in advanced stages) treated with Romidepsin
at a starting dose of 14mg/m2 infused over 4 hours on days
1, 8, and 15 every 28 days. The endpoint for both studies
was the overall response rate (ORR). Median time to ﬁrst
response was 2 months in both studies and ORR was 34%
and 35%, respectively. The median duration of response was
15 and 13.7 months, respectively. Adverse eﬀects observed in
both studies were similar to the toxicities observed in phase I
trials. Common (any grade) adverse eﬀects included nausea
(56% and 86%, resp.), fatigue (53% and 77%), vomiting
(34%and52%),and anorexia (23%and54%).Furthermore,
consistently with the toxicity pattern shown by Romidepsin
in Phase I studies [60], ECG changes were also noted in
a large proportion of patients of the study (up to 50%)
consisting of T-wave ﬂattening, ST tract depression, and QT
interval prolongation. Cardiotoxicity, which has not been
frequently found after Vorinostat treatments, seems to be
a more speciﬁc side eﬀect of Romidepsin and has been
explained as being dependent upon the interaction of the
drug with the HERG K+ channels [3]. Romidepsin has also
been initially tested clinical conditions other than CTCL. In
some Phase I/II trials, single-agent Depsipeptide has shown
a limited clinical beneﬁt in treating refractory neoplasms,
including AML/MDS, CLL, lung cancer, hormone refractory
prostate cancer, and renal cell cancer [61–66].
6.Mecetinostat (MGCD0103)
Mecetinostat(MGCD0103)isaclassIisotype-selectiveorally
available benzamide HDACs inhibitor. Early clinical trials
have demonstrated activity in hematological malignancies,
includingmyeloidleukemiaand lymphoma andwas well tol-
erated with DLTs of fatigue, nausea, vomiting, and diarrhea.
A phase I trial resulted in a bone marrow CR in three of 29
patientswithAMLataMTDof60mg/m2 administered three
times weekly [67]. A phase II study in adults with relapsed
or refractory DLBCL (33 patients) or follicular lymphoma
(FL—17 patients) also demonstrated signiﬁcant anticancer
activity. Most of the 17 patients with DLBCL that were
reassessed by CT after treatment showed a decrease in tumor
volume,aswell asoneCRand 3PRs.Outoftenpatientswith
FL, one achieved PR. Grade 3 toxicities or greater included
fatigue, neutropenia, thrombocytopenia, and anemia [68]. A
phase II trial was also conducted in patients with relapsed
or refractory Hodgkin’s lymphoma. A treatment schedule of
110mg or 85mg three times per week in a 4-week cycle were
givento23and 10patients, respectively.Fromthe21patients6 Journal of Biomedicine and Biotechnology
evaluated from the 110mg cohort, there was an ORR of 38%
( 2h a dC R s ,a n d6h a dP R s ) .T h ep a t i e n t sw h oh a dC R s
remained with progression free survival for >270 and >420
days, respectively. From the 10 patients in the 85mg cohort,
all 5 that were evaluated demonstrated tumor reductions of
≥30%, with one PR and 2SDs [69].
Aside from the beneﬁcial eﬀects demonstrated in hema-
tological malignancies, MGCD0103 also demonstrated clin-
ical beneﬁts in solid tumor treatment. A phase I trial
in patients with advanced solid tumors given MGCD0103
three times per week for 2 of every 3 weeks showed
tolerable DLTs of fatigue, nausea, vomiting, anorexia, and
dehydration. After four or more cycles, SD was observed
in ﬁve of 32 patients. A phase II dose of 45mg/m2/day
was recommended [70]. Phase I/II studies in solid tumors
werealsoconductedincombinationwith gemcitabine.Phase
I included patients with refractory solid tumors. Phase
II was limited to gemcitabine naive patients with locally
advanced or metastatic pancreatic cancer. During a 28-day
cycle patients received MGCD0103 three times per week in
a dose ascending 3 + 3 design targeting a DLT of <33%.
Gemcitabine was administered three times per cycle weekly
at 1000mg/m2. Out of the 14 patients evaluated, there were
2PRs in patients with pancreatic carcinoma, one PR in
a patient with nasopharyngeal cancer, and one PR in a
patient with cutaneous T-cell lymphoma. The phase II trial
is ongoing at a dose of 90mg for patients with pancreatic
cancer [71].
7.Panobinostat (LBH589)
Panobinostat is a hydroxamate that has shown potential in
early phase I and II clinical trials. In an initial trial, 15
patients with AML, ALL, or MDS were treated with 4.8
to 14mg/m2 panobinostat administered intravenously as a
30-minute infusion. Transient blast cell reductions occurred
in 8 of 11 patients with peripheral blasts. Four patients
exhibited a DLT of grade 3 QTcF prolongation at 14mg/m2,
which were asymptomatic and clearedaftertreatment ended.
Common toxicities included nausea, diarrhea, vomiting,
hypokalemia, loss of appetite, and thrombocytopenia [72].
CTCL patients (stage IB-IVA), including Mycosis Fungoides
(MF) and Sezary Syndrome (SS), who have failed two or
more previous therapies were enrolled in a phase II clinical
trail. Panobinostat was administered at 20mg orally on days
1, 3, and 5 weekly until disease progression or intolerance to
twogroupsofpatients,onewhohadreceivedpriortreatment
with oral bexorotene and a second without. The best overall
responses were 3PRs and 4SDs. ECG monitoring of QTcF
prolongation was performed, without any >500ms [73].
8.Belinostat(PXD101)
Belinostat has shown promising anticancer activity in both
hematologic malignancies as well as solid tumors. In a
trial enrolling 16 patients with advanced hematological
neoplasms, belinostat was administered intravenously at one
of three dose levels: 600, 900, and 1000mg/m2/d. While
no CRs or PRs were noted, intravenous administration was
well tolerated, and ﬁve patients (including two with DLBCL)
achieved SDs after 2–9 treatment cycles. There were no
grade 3 or 4 hematological toxicities (except one case of
grade 3 lymphopenia), and the most common adverse eﬀects
were nausea, vomiting, fatigue and ﬂushing. There were two
grade 4 renal failures in patients with multiple myeloma
(MM). The recommended dose for phase II studies was
1000mg/m2/d, intravenously administered on days 1–5 of a
21-day cycle for patients with hematological neoplasia [74].
For solid tumors, Belinostat was tested in a phase I
study of patients with advanced refractory cancers. The
46 patients received six dose levels, ranging from 150
to 1200mg/m2/d over a 5-day cycle. DLTs were fatigue,
diarrhea, atrial ﬁbrillation, and grade 2 nausea/vomiting,
which led to inability to complete the full cycle. 39% of
patientsresultedinSD.Ofthe24patientstreatedattheMTD,
which was determined to be 1000mg/m2/d, 50% achieved
SD [75]. Patients with platinum resistant epithelial ovarian
cancer (EOC) are resistant to conventional chemotherapy.
Belinostat was administered intravenously at 1000mg/m2/d
on days 1–5 of a 21-day cycle to metastatic or recurrent
platinum resistant EOC and low malignant potential (LMP)
ovarian tumors. Of the 18 patients with LMP, 1 had PR, 10
had SDs.MedianPFSinLMPwas13.4months. Patientswith
EOC 9 had SD with a median PFS of 2.3 months [76].
9.Entinostat(MS-27-275)
Clinical trials of Entinostat, a benzamide derivative, initiated
in2005with a Phase Istudy enrolling patientswith advanced
solid tumors or lymphoma. Entinostat was administered to
a total of 22 patients once a week for 4 weeks during a 6-
weekcycle.TheMTDwasdeterminedtobe6mg/m2,andthe
common DLTs were hypophophatemia, hyponatremia, and
hypoalbuminemia, which were all reversible [77]. After the
analysis of three diﬀerent dose schedules, 4mg/m2 weekly or
2t o6m g / m 2 every other week, for three weeks in a 28-day
cycle; the biologically relevant plasma concentrations and
antitumor activity were determined [78].
In solid tumors, a phase I combination therapy trial
was performed on ten patients with an advanced NSCLC.
Patients were treated with 5-azacitidine (AZA), a DNA
methyltransferase inhibitor, subcutaneouslyon days 1–6 and
8–10 along with a ﬁxed dose (7mg/m2)o nd a y3a n d1 0o f
a 28-day cycle of entinostat. The dose of AZA was varied
by cohort using a standard 3 + 3 dose assessment. No DLTs
were observed in the 30mg/m2 dose cohort. However, in
the 40mg/m2 cohort, after one week, a patient was replaced
due to rapidly progressing disease, and another patient
experienced a grade 3 neutropenia and thrombocytopenia.
The common toxicities included injection site reactions,
nausea/vomiting, constipation, fatigue, and cytopenias. One
patient had a PR, which continued longer than 8 months.
Two patients had SDs and the remaining patients had PODs
[79].
10.ValproicAcid
Valproic acid (VPA) has been increasingly studied in clinical
trials for a variety of cancer types as a single agent or inJournal of Biomedicine and Biotechnology 7
combination with other therapies. In solid tumors, VPA
was analyzed for activity in 12 patients with cervical cancer.
Three four-patient dose cohorts were formed, for 20mg/kg,
30mg/kg,and40mg/kgadministered orallyforﬁvedaysover
a six-day protocol. Tumor-deacetylase activity decreased in
eight patients in a statistically signiﬁcant manner. A grade
2 depression in level of consciousness was registered in 9
patients [80]. Another phase I study in 26 patients revealed
neurocognitive impairment, with grade 3 or 4 neurological
side eﬀects in 8 of the 26 patients. When administered
intravenously the MTD was determined to be 60mg/kg/d
[81]. A phase II study for the treatment of advanced solid
tumors with hydralazine and VPA revealed clinical beneﬁt
in 80% (12) of patients with cervix, breast, lung, testis, and
ovarian carcinomas. Four patients had PRs and eight SDs,
and the most common toxicity was hematological [82].
VPA has been more frequently studied in the use of
combinationtherapies, speciﬁcally with all transretinoic acid
(ATRA). From a study of 75 patients with AML/MDS,
66 were initially treated with VPA monotherapy followed
by ATRA in nonresponsive or relapsed patients. VPA was
administered for a median treatment duration of 4 months
and ATRA, 2 months. 24% of patients showed hematological
improvement with a median response duration of 4 months.
Four out of 10 relapsed patients, when administered ATRA
had a second response and both treatments were well
tolerated [83]. VPA was also combined with both AZA as
well as ATRA in patients with AML or high-risk MDS. A
totalof 53patients were treated with AZA at theﬁxed dose of
75mg/m2 daily for 7 days, ATRA at 45mg/m2 orally daily for
5 days starting on day 3, and VPA, which was dose escalated
and administered orally daily for 7 days concomitantly. The
ORR was found to be 42%, the median remission duration
was26weeks,theMTDforVPA was50mg/kgdailyfor7days
and the DLT was reversible neurotoxicity [84]. In another
study of patients with AML/MDS, increasing doses of VPA
administered orally and concomitantly with a ﬁxed dose of
decitabine (15mg/m2 by intravenous daily infusion) for 10
days revealed a safe daily dose of 50mg/kg. 22% (12) of
patients had an objective response, this included 10CRs and
2CRs with incomplete platelet recovery [85].
11.AssociationsofHDACsInhibitors with
Other TargetDrugs
Despite the very high number of gene products potentially
deregulated in solid tumors, high throughput screening
analyses suggest that mutations often occur in genes that
collaborate in a relatively limited pool of common cell
signaling pathways [86]. This hypothesis may have a great
relevance in the clinic. In fact, having at hand several
classes of eﬀective “pathway-oriented” target drugs, and
admitting that a tumor may be driven by a limited number
of deregulated pathways, it possible that the concomitant use
ofacombinationofdrugsdirected againstdiﬀerentpathways
functionally related may resultin an improvedantineoplastic
eﬀect or in the overcoming of drug resistance.
Recent studies on multiple myeloma (MM) models sug-
gest that HDACs inhibitors may synergize with proteasome
inhibitors. Although the molecular mechanism underlying
this eﬀect is not completely understood several means have
been proposed [87] and encouraging data has come from
the early clinical experimentation, including a phase I trial
[88] of randomized patients with relapsed/refractory MM
to receive Vorinostat (200mg twice daily or 400mg once
daily for 14 days) in combination with bortezomib (0.7 or
0.9mg/m2on days 4, 8, 11, and 15 or 0.9 or 1.1 or 1.3mg/m2
on days 1, 4, 8, and 11). Among 34 evaluable patients, the
best response to vorinostat plus bortezomib was a partial
response (PR) in 9 (26%) patients, minimal response (MR)
in 7 (21%) patients, and stable disease (SD) in 18 (53%)
patients. Mean duration of SD was 89 days, range 9–369
days. Of the 13 evaluable patients who had previously been
treated with bortezomib, 5 achieved a PR, 1 had an MR,
and 7 had SD. Eleven of the 34 patients enrolled (32.4%)
discontinued treatment due to adverse eﬀects (AEs). Most
common AEs were fatigue, nausea, diarrhea, and hemato-
logical toxicities. A phase II open label study from the same
group is currently ongoing. Another Phase I trial accrued 23
heavily pretreated (median of 7 previous regimens) patients
with relapsed/refractory MM to receiving escalating doses
of Bortezomib (1 or 1.3mg/m2 on days 1, 4, 8, and 11
and Vorinosat 100mg twice daily, 200mg twice daily, and
400mg once daily, or 500mg once daily for 8 days each
21-day cycle). Overall response rate was 42%, two patients
receiving 500mg vorinostat had prolonged QT interval and
fatigue as dose-limiting toxicities. The most common grade
>3 toxicities were myelosuppression (n = 13), fatigue
(n = 11), and diarrhea (n = 5). In the same setting of
patients with relapsed/refractory MM, the combination of
Romidepsin and Bortezomib and Dexamethasone has also
shown promising results. In a Phase I/II trial, of 18 evaluable
patients, this schedule resulted in a overall response rate
of 67%. The most common drug related grade 3 toxicities
included fatigue (2pts.), neutropenia (1pts.), sepsis (2pts.),
and peripheral neuropathy (1pts). Preclinical data seems to
conﬁrm a synergic eﬀect of Panobinostat and Bortezomib,
and a Phase I trial is currently ongoing (NCT00532389).
These encouraging results are paving the way to a relevant
number of trials testing the association of diﬀerent HDAC
and Proteasome inhibitors, and results are expected in a
relatively short time.
12.HDACsInhibitor-Related Toxicity
The relationship between the toxicity of HDACs inhibitors
and their pharmacodynamic/pharmacokinetic properties is
still largely unknown. This makes it diﬃcult to optimize
HDACs inhibitors treatment. Studies in preclinical models
have shown that HDACs inhibitors are a class of agents that
has been generally well tolerated and proved a very good
toxicity proﬁle in comparison with other chemotherapeutic
drugs used in cancer therapy. The main adverse eﬀect
is fatigue, which is generally mild and tolerable in most
patients, but in 30% of patients, it can be severe enough
to cause drug discontinuation. Gastrointestinal toxicities are
also common side eﬀectsand includeanorexia, nausea, vom-
iting, and diarrhea. Overall, they are mild and controllable8 Journal of Biomedicine and Biotechnology
with symptomatic treatment. Biochemical disorders such as
hypokalemia, hyponatremia, hypocalcemia, hyperglycemia,
hypophosphatemia, and hypoalbuminemia are common
with various HDACs inhibitors, while neurocortical distur-
bances including somnolence, confusion, and tremor are
observed mainly with phenylbutyrate and valproic acid. All
these side eﬀects are generally reversible upon cessation of
administration of the drug.
Another side eﬀect of histone deacetylase inhibitors is
transient thrombocytopenia that is relatively common with
most HDACs inhibitors [89], it is generally mild, although
has been dose limiting in some studies.
A signiﬁcant adverse reaction regards the cardiotoxicity.
Early studies in preclinical animal models have shown
that various HDACs inhibitors such as Romidepsin are
able to cause myocardial inﬂammation and cardiac enzyme
elevation. These studies represent a controversial issue since
highdosesofHDACsinhibitors wereused[90,91]compar ed
to the doses that were conﬁrmed appropriate for use in
PhaseItrials.Speciﬁcally,theeﬀectofRomidepsinoncardiac
function was assessed in 42 patients with T-cell lymphoma.
They received a total of 736 doses of Romidepsin and an
intensive cardiac monitoring was evaluated [92]. Grade I (T-
wave ﬂattening) and grade II (ST segment depression) ECG
changes occurred in more than half of the ECGs obtained
post treatment; however, these changes were reversible and
of short duration, with no elevation in cardiac enzymes and
no signiﬁcant changes in left ventricular ejection fraction.
In addition, cardiac dysrhythmias were observed in
a small number of patients but most of these patients
had pretreatment documented dysrhythmias. Similar ECG
changes and QT-interval prolongation have been reported
in other Phase I/II Romidepsin studies [60, 66, 93–96]. In
other Romidepsin studies, there have been reports of sudden
death; however, the relationship to the drug remains unclear.
In particular, a Phase II study of 15 patients with metastatic
neuroendocrine tumors, administered with standard doses
of Romidepsin reported one sudden death in a 48-year-
old patient [66]. However, this patient had a history of
hypertension, and a biventricular hypertrophy was revealed
by postmortem examination, both are known risk factors
for sudden death. Cardiotoxicity may be a class eﬀect of
HDACs inhibitors, being more frequent with Romidepsin
and other class-I inhibitors rather than Vorinostat and
other pan-HDAC inhibitors but it is unlikely that these
side reactions are limited just to those HDACs inhibitors.
Additional parallel cardiotoxicity studies with other various
HDACs inhibitors are necessary.
Possible room for improvement could be in the devel-
opment of isoform-selective HDACs inhibitors (extensively
reviewed in [97]). It is known from knockout studies
that the deletion of some speciﬁc HDACs isoforms can
cause precise phenotypic defects. In particular, mice lacking
some of the HDACs isoforms (namely, HDAC2, HDAC3,
HDAC5, and HDAC9) show severe cardiac malformations
anddysfunctions [98,99],suggestingthat HDACsinhibitors,
speciﬁc for other HDACs could possibly have a better
cardiotoxicity proﬁle still retaining the full pro-apoptotic
action. Furthermore the introduction of reliable sensitivity
biomarkers in the design of trials will allow a better strati-
ﬁcation of patients thus minimizing the risk of exposure of
the unresponsive subjects to HDACs treatment and toxicity.
Recently, a genome-wide loss-of-function screening was
undertaken to reveal genes that govern tumor cell sensitivity
to HDAC inhibitors in a sarcoma cell model, and HR23B,
a protein involved in shuttling ubiquitinated proteins to
the proteasome was identiﬁed as a potential biomarker
[100]. HR23B expression was further investigated in 21 skin
biopsiesfrom 20patientswith CTCL enrolled ina Vorinostat
Phase II trial [46] and analyzed by immunohistochemistry.
The proportion of patients with a strong HR23B staining
who hadaclinicalresponse was69%,thussuggestingapretty
high positive predictive value(PPV). Similar PPV for HR23B
were obtained when looking at patients treated with other
HDACs inhibitors [101].
13.Conclusions
HDAC, inhibitors represent a promising new group of
anticancer agents, even though the mechanisms of HDAC
inhibitor-induced tumor cell death require further eluci-
dation. While vorinostat and romidepsin are the only US
FDA-approvedHDACsinhibitorscurrentlyutilizedincancer
therapy, as we have shown here, there are many HDACs
inhibitors that are presently under intense clinical inves-
tigation, both as single agents and combination therapies.
These will hopefully be able to further improve the range of
treatment options available for hematologic malignancies as
well as for solid tumors.
As we come closer to understanding the molecular
mechanisms inherentlyresponsiblefortumorigenesis,aswell
as the full range of HDACs inhibitor cellular actions, we
will be able to target in a more appropriate way and be
able to pair cancer therapies for clinical use. In order to
establish rigorous patient selection criteria and optimal drug
combinations to properly design further trials and maximize
the clinical gain, the bridge between the biological function
and thetherapeuticbeneﬁt ofthese drugs needs to be further
elucidated.
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